An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation.

Autor: Dooghaie Moghadam A; Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Eslami P; Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Dowlati Beirami A; Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Iravani S; Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran., Farokhi E; Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran., Mansour-Ghanaei A; Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Guilan, Iran., Hashemi MR; Gastroenterology and Hepatobiliary Research Center, AJA University of Medical Sciences, Tehran, Iran., Aghajanpoor Pasha M; Gastroenterology and Hepatobiliary Research Center, AJA University of Medical Sciences, Tehran, Iran., Mehrvar A; Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran., Nassiri-Toosi M; Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Jazyk: angličtina
Zdroj: Middle East journal of digestive diseases [Middle East J Dig Dis] 2021 Jan; Vol. 13 (1), pp. 5-14. Date of Electronic Publication: 2021 Mar 02.
DOI: 10.34172/mejdd.2021.197
Abstrakt: Currently, liver transplantation (LT) is considered as the only option for the treatment of patients with various causes of liver failure, including patients with chronic hepatitis B virus (HBV) infections. Overall, patients with HBV who undergo LT are at increased risk of hepatitis B infection recurrence. Although the current knowledge regarding the pathophysiology of this infection has been dramatically increased over the past few decades, it is still considered a complex disease process with varying degrees of clinical characteristics and changing patterns over time. There are various treatment strategies for preventing HBV recurrence in the LT setting. Generally, these regimens include oral nucleoside/ nucleotide analogues (NAs), hepatitis B immune globulin (HBIG), and vaccines or the combination of these drugs. The treatment strategy of choice should be based on cost-effectiveness, along with other patients underlying conditions. In this case, studies indicate that potent NAs are more cost-effective than HBIG in most case scenarios. In this article, we aimed to review the general medications used in the prophylaxis of the recurrence of HBV infection after LT.
Competing Interests: CONFLICT OF INTEREST The authors declare no conflict of interest related to this work.
(© 2021 The Author(s).)
Databáze: MEDLINE
Externí odkaz: